Мақола

Epigenetic regulation of non-apoptotic regulated cell death

Amr Ali Mohamed Abdelgawwad El-SehrawyInternal medicine, Diabetes, Endocrinology and Metabolism, Mansoura University, Mansoura, Egypt. Electronic address: [email protected]Ghaleb OriquatFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Electronic address: [email protected]Lola RazyikovaSamarkand State Medical InstituteHilola Ne'matovaDepartment of Allergology, Clinical Immunology, Microbiology, Tashkent State Medical University, Tashkent, Uzbekistan. Electronic address: [email protected]Navruzbek ErgashevDepartment of Surgery, Termez University of Economics and Service, Termez, Uzbekistan. Electronic address: [email protected]Naji Musa AliDepartment of Pharmacy, College of Pharmacy, The Islamic University, Najaf, Iraq. Electronic address: [email protected]Neeraj BainsalCentre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab 140401, India. Electronic address: [email protected]Ritesh SinghCentre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab 140401, India. Electronic address: [email protected]

2026en

ABI

Аннотация

For decades, apoptosis has reigned supreme in cell death therapeutics, yet its clinical limitations in resistant cancers and degenerative diseases have unveiled the critical role of non-apoptotic regulated cell death (RCD) pathways, including ferroptosis, necroptosis, pyroptosis, and parthanatos. This review examines chromatin as a key regulatory layer influencing these pathways through dynamic histone modifications, DNA methylation, non-coding RNAs, and 3D genome architecture. We dissect how chromatin landscapes integrate metabolic, oxidative, and inflammatory signals in a cell-type- and lineage-dependent manner to steer cell fate, thereby enabling context-specific RCD activation or suppression. Emerging evidence suggests that epigenetic dysregulation can silence tumor-suppressive cell-death regulators such as GSDME and RIPK3 in some cancers and may contribute to neuronal susceptibility to parthanatos in specific neurodegenerative models. Therapeutically, the reversibility of epigenetic marks makes HDAC/DNMT inhibitors, BET-targeting agents, and CRISPR/dCas9-based editing attractive candidates for re-sensitizing selected preclinical models to RCD inducers; however, their clinical value will depend on improving tissue selectivity, minimizing toxicity, and demonstrating durable efficacy in heterogeneous patient tumors. Nanotechnology may improve delivery, but it does not fully overcome systemic exposure or targeting barriers. Emerging frontiers (single-cell epigenomics, phase-separated biomolecular condensates, and mitochondrial-nuclear crosstalk) may help identify candidate biomarkers and vulnerabilities, but these remain incompletely validated. By shifting from a genetic to a chromatin-centric paradigm and explicitly accounting for cell-type-specific chromatin states, this review highlights a promising framework for overcoming cell-death resistance, while recognizing that most pathway links, biomarkers, and delivery strategies still require robust validation in vivo and across patient cohorts before broad clinical translation.

Ҳали таржима қилинмаган

Идентификаторлар

DOI: 10.1016/j.ejcb.2026.151552

Иқтибослар ва манбалар

0 та иқтибос301 та фойдаланилган манба